文献速递心力衰竭与心肌病心律失常

右室起搏升级心脏再同步治疗在心力衰竭中的随机试验

Upgrade of right ventricular pacing to cardiac resynchronization therapy in heart failure: a randomized trial.
PubMed 文献 · Eur Heart J · 2023-01-01

这项多中心随机对照试验纳入360例有高右室起搏负荷(≥20%)和宽起搏QRS波(≥150 ms)的症状性HFrEF患者,随机接受CRT-D升级或ICD治疗。

要点

  • 高右室起搏负荷的HFrEF患者升级CRT-D可显著降低主要复合终点风险。
  • CRT-D组全因死亡或心衰住院风险显著低于ICD组(HR 0.27,95%CI 0.16-0.47)。
  • 两组手术或器械相关并发症发生率相似(12.3% vs 7.8%)。

核心结论

  • 在具有显著右室起搏负荷和射血分数降低的起搏器或ICD患者中,与ICD治疗相比,升级至CRT-D降低了全因死亡、心衰住院或逆重构缺失的复合风险。

研究设计与样本

  • 多中心、随机、对照试验,纳入360例症状性(NYHA II-IVa)HFrEF患者,具有起搏器或ICD、高右室起搏负荷≥20%和宽起搏QRS波持续时间≥150 ms。
  • 按3:2比例随机分配至CRT-D升级组(n=215)或ICD组(n=145)。
  • 主要终点为12个月时评估的全因死亡、心衰住院或左室收缩末期容积缩小<15%的复合终点。

主要发现

  • 手术或器械相关并发症发生率两组相似:CRT-D组25/211(12.3%),ICD组11/142(7.8%)。

关键数值与推荐

  • 纳入标准:症状性(NYHA II-IVa)HFrEF,起搏器或ICD,高右室起搏负荷≥20%,宽起搏QRS波持续时间≥150 ms。
  • 主要终点:12个月时全因死亡、心衰住院或左室收缩末期容积缩小<15%的复合终点。

临床怎么用

  • 对于有高右室起搏负荷(≥20%)和宽起搏QRS波(≥150 ms)的HFrEF患者,可考虑将起搏器或ICD升级为CRT-D以降低不良事件风险。

局限性

  • 中位随访时间较短(12.4个月),长期获益需进一步验证。
  • 主要终点中左室收缩末期容积缩小<15%的评估基于12个月时部分患者数据(CRT-D组179例,ICD组128例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: De novo implanted cardiac resynchronization therapy with defibrillator (CRT-D) reduces the risk of morbidity and mortality in patients with left bundle branch block, heart failure and reduced ejection fraction (HFrEF). However, among HFrEF patients with right ventricular pacing (RVP), the efficacy of CRT-D upgrade is uncertain. METHODS: In this multicentre, randomized, controlled trial, 360 symptomatic (New York Heart Association Classes II-IVa) HFrEF patients with a pacemaker or implantable cardioverter defibrillator (ICD), high RVP burden ≥ 20%, and a wide paced QRS complex duration ≥ 150 ms were randomly assigned to receive CRT-D upgrade (n = 215) or ICD (n = 145) in a 3:2 ratio. The primary outcome was the composite of all-cause mortality, heart failure hospitalization, or <15% reduction of left ventricular end-systolic volume assessed at 12 months. Secondary outcomes included all-cause mortality or heart failure hospitalization. RESULTS: Over a median follow-up of 12.4 months, the primary outcome occurred in 58/179 (32.4%) in the CRT-D arm vs. 101/128 (78.9%) in the ICD arm (odds ratio 0.11; 95% confidence interval 0.06-0.19; P < .001). All-cause mortality or heart failure hospitalization occurred in 22/215 (10%) in the CRT-D arm vs. 46/145 (32%) in the ICD arm (hazard ratio 0.27; 95% confidence interval 0.16-0.47; P < .001). The incidence of procedure- or device-related complications was similar between the two arms [CRT-D group 25/211 (12.3%) vs. ICD group 11/142 (7.8%)]. CONCLUSIONS: In pacemaker or ICD patients with significant RVP burden and reduced ejection fraction, upgrade to CRT-D compared with ICD therapy reduced the combined risk of all-cause mortality, heart failure hospitalization, or absence of reverse remodelling.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Merkely B, Hatala R, Wranicz JK, et al. Upgrade of right ventricular pacing to cardiac resynchronization therapy in heart failure: a randomized trial. Eur Heart J. 2023. PMID: 37632437. doi:10.1093/eurheartj/ehad591

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。